AceLink Therapeutics has opened its first clinical site in China for a Phase 2 clinical trial testing AL01211 as a…
Andrea Lobo, PhD
Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo, PhD
AceLink Therapeutics’ Phase 2 trial testing AL1211 as a treatment for Fabry disease has been cleared to launch…
Periostin, a protein associated with kidney injury, may be a valuable biomarker of Fabry disease’s related kidney damage, according…